Pfizer reports positive Phase 3 results for vitiligo drug LITFULO
Pfizer announced that its once-daily drug LITFULO (ritlecitinib) demonstrated significant improvements in facial and total body repigmentation compared to a placebo in two Phase 3 trials for nonsegmental vitiligo. The company plans to submit for regulatory approval in the US and EU.
Pfizer said two Phase 3 trials found that once-daily LITFULO (ritlecitinib) significantly improved facial and total body repigmentation versus placebo in nonsegmental vitiligo. The company said it plans global regulatory submissions, including to the FDA and EMA.